Prior Auth Required

00241 - multicenter trial. The Lancet: Neurology. 2021;20(12)1012-1026. doi:10.1016/s1474-4422(21) -6

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Servicemulticenter trial. The Lancet: Neurology. 2021;20(12)1012-1026. doi:10.1016/s1474-4422(21) -6
Procedure / Service Description

Updated Accessed - Diaz-Manera J, Kishnani P, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus 12/2021 12/2021 alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomized, multicenter trial. The Lancet: Neurology. 2021;20(12)1012-1026. doi:10.1016/s1474-4422(21)00241-6 Vanherpe P, Fieuws S, D’Hondt A, et al. Late-onset Pompe disease (LOPD) in Belgium: clinical 04/2020 11/2023 characteristics and outcome measures. Orphanet J Rare Dis. 2020;15(83). doi:10.1186/s13023-020-

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.